JP2012247438A5 - - Google Patents

Download PDF

Info

Publication number
JP2012247438A5
JP2012247438A5 JP2012198693A JP2012198693A JP2012247438A5 JP 2012247438 A5 JP2012247438 A5 JP 2012247438A5 JP 2012198693 A JP2012198693 A JP 2012198693A JP 2012198693 A JP2012198693 A JP 2012198693A JP 2012247438 A5 JP2012247438 A5 JP 2012247438A5
Authority
JP
Japan
Prior art keywords
inhibitor
cancer
leukemia
igfbp2
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012198693A
Other languages
English (en)
Japanese (ja)
Other versions
JP5816147B2 (ja
JP2012247438A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012247438A publication Critical patent/JP2012247438A/ja
Publication of JP2012247438A5 publication Critical patent/JP2012247438A5/ja
Application granted granted Critical
Publication of JP5816147B2 publication Critical patent/JP5816147B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012198693A 2006-06-30 2012-09-10 Ｉｇｆｂｐ２インヒビター Active JP5816147B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81800406P 2006-06-30 2006-06-30
US60/818,004 2006-06-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2009518353A Division JP5399900B2 (ja) 2006-06-30 2007-06-29 Ｉｇｆｂｐ２インヒビター

Publications (3)

Publication Number Publication Date
JP2012247438A JP2012247438A (ja) 2012-12-13
JP2012247438A5 true JP2012247438A5 (enExample) 2013-03-28
JP5816147B2 JP5816147B2 (ja) 2015-11-18

Family

ID=38783580

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2009518353A Active JP5399900B2 (ja) 2006-06-30 2007-06-29 Ｉｇｆｂｐ２インヒビター
JP2012198693A Active JP5816147B2 (ja) 2006-06-30 2012-09-10 Ｉｇｆｂｐ２インヒビター
JP2013024276A Pending JP2013127473A (ja) 2006-06-30 2013-02-12 Ｉｇｆｂｐ２インヒビター

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2009518353A Active JP5399900B2 (ja) 2006-06-30 2007-06-29 Ｉｇｆｂｐ２インヒビター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013024276A Pending JP2013127473A (ja) 2006-06-30 2013-02-12 Ｉｇｆｂｐ２インヒビター

Country Status (7)

Country Link
US (2) US20080112888A1 (enExample)
EP (2) EP2032989B2 (enExample)
JP (3) JP5399900B2 (enExample)
AT (1) ATE537450T1 (enExample)
CA (1) CA2655997A1 (enExample)
ES (1) ES2427924T3 (enExample)
WO (1) WO2008005469A2 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ536475A (en) * 2002-05-24 2008-06-30 Schering Corp Neutralizing human anti-igfr antibody
PE20050928A1 (es) * 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
DE602005025685D1 (de) * 2004-12-03 2011-02-10 Schering Corp Biologische marker zur vorauswahl von patienten für die anti-igf1r-therapie
CN108421044A (zh) 2005-02-03 2018-08-21 综合医院公司 治疗吉非替尼耐药性癌症的方法
US20060233810A1 (en) * 2005-04-15 2006-10-19 Yaolin Wang Methods and compositions for treating or preventing cancer
BRPI0618042A2 (pt) 2005-11-04 2011-08-16 Wyeth Corp usos de uma rapamicina e de uma herceptina, produto, pacote farmacêutico, e, composição farmacêutica
US20080112888A1 (en) † 2006-06-30 2008-05-15 Schering Corporation Igfbp2 biomarker
EP2089055A4 (en) * 2006-11-01 2011-02-02 George Mason Intellectual Prop METHOD FOR THE DETECTION AND CONTROL OF CANCER
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
EP2247757A2 (en) * 2007-12-18 2010-11-10 Schering Corporation Biomarkers for sensitivity to anti-igf1r therapy
EP2259797A2 (en) * 2008-03-25 2010-12-15 Schering Corporation Methods for treating or preventing colorectal cancer
JP5646457B2 (ja) * 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
EP3002299A1 (en) * 2008-06-03 2016-04-06 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
PE20100054A1 (es) * 2008-06-03 2010-03-03 Abbott Lab Inmunoglobulina con dominio variable dual
CN102641270A (zh) 2008-06-17 2012-08-22 惠氏有限责任公司 含有hki-272和长春瑞滨的抗肿瘤组合
WO2009154645A1 (en) * 2008-06-20 2009-12-23 Smithkline Beecham Corporation Methods for the treatment of central nervous system tumors
MX2010014574A (es) * 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
US8669273B2 (en) 2008-08-04 2014-03-11 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
EP2376116B1 (en) 2008-12-12 2015-12-09 Boehringer Ingelheim International GmbH Anti-igf antibodies
US8410144B2 (en) 2009-03-31 2013-04-02 Arqule, Inc. Substituted indolo-pyridinone compounds
IL264349B2 (en) 2009-04-06 2024-01-01 Wyeth Llc Regimen comprising neratinib for the treatment of cancer
MX2011011670A (es) * 2009-05-01 2011-11-18 Abbott Lab Inmunoglobulinas de dominio variable dual y usos de las mismas.
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
MX2012004415A (es) * 2009-10-15 2012-05-08 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011133636A1 (en) * 2010-04-20 2011-10-27 Cedars-Sinai Medical Center COMBINATION THERAPY WITH CD4 LYMPHOCYTE DEPLETION AND mTOR INHIBITORS
US8741288B2 (en) * 2010-07-07 2014-06-03 Chang Gung Medical Foundation, Linkou Branch Protein markers for detecting liver cancer and method for identifying the markers thereof
US20130345322A1 (en) * 2010-07-14 2013-12-26 Commonwealth Scientific And Industrial Research Organisation Diagnostic for colorectal cancer
US8735546B2 (en) 2010-08-03 2014-05-27 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
WO2012019031A2 (en) * 2010-08-04 2012-02-09 Ohio University Biomarkers for growth hormone disorders
PH12013500337A1 (en) 2010-08-26 2017-08-23 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
US20130338033A1 (en) * 2011-01-27 2013-12-19 Virginia Commonwealth University Diagnostic and Prognostic Markers for Metastasis
AU2012212075A1 (en) 2011-02-02 2013-07-18 Amgen Inc. Methods and compositons relating to inhibition of IGF-1R
WO2012116040A1 (en) 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
JP2014519813A (ja) 2011-04-25 2014-08-21 オーエスアイ・ファーマシューティカルズ，エルエルシー 癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
US9120870B2 (en) 2011-12-30 2015-09-01 Abbvie Inc. Dual specific binding proteins directed against IL-13 and IL-17
CN102703502A (zh) * 2012-02-27 2012-10-03 同昕生物技术（北京）有限公司 Rta蛋白的制备方法及其在鼻咽癌检测试剂中的应用
US20150079623A1 (en) * 2012-03-18 2015-03-19 Kyushu University, National University Corporation Apparatus, system and method for analyzing disease sample
EP2883057B1 (en) * 2012-08-09 2018-12-05 Institut National de la Sante et de la Recherche Medicale (INSERM) Diagnostic of heart failure
AU2013337775B2 (en) 2012-11-01 2017-03-30 Abbvie Inc. Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof
WO2014070523A1 (en) * 2012-11-02 2014-05-08 Repros Therapeutics Inc. Trans-clomiphene for use in cancer therapy
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
EP2970459A2 (en) 2013-03-15 2016-01-20 AbbVie Inc. Dual specific binding proteins directed against il-1beta and il-17
PT3004891T (pt) 2013-06-06 2019-05-30 Inst Nat Sante Rech Med Biomarcador de re-hospitalização após uma insuficiência cardíaca
WO2015120198A1 (en) 2014-02-05 2015-08-13 Cedars-Sinai Medical Center Methods and compositions for treating cancer and infectious diseases
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
TW202228775A (zh) 2020-10-14 2022-08-01 美商維里迪恩醫療股份有限公司 用於治療甲狀腺眼病之組合物及方法
TW202320850A (zh) 2021-08-10 2023-06-01 美商維里迪恩醫療股份有限公司 用於治療甲狀腺眼病之組合物、劑量及方法
IL326876A (en) * 2023-09-06 2026-04-01 Viridian Therapeutics Inc Pharmaceutical preparations of anti-IGF-1R antibodies

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
DE3668186D1 (de) 1985-04-01 1990-02-15 Celltech Ltd Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5196446A (en) 1990-04-16 1993-03-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Certain indole compounds which inhibit EGF receptor tyrosine kinase
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5654307A (en) 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
US5656655A (en) 1994-03-17 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Styryl-substituted heteroaryl compounds which inhibit EGF receptor tyrosine kinase
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
US6294349B1 (en) * 1999-03-01 2001-09-25 University Of Mississippi Medical Ctr. Method of diagnosing and monitoring malignant breast carcinomas
US6316462B1 (en) * 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
CZ303660B6 (cs) 1999-05-21 2013-02-13 Bristol-Myers Squibb Company Pyrrolotriazin a farmaceutický prostredek s jeho obsahem
EP1191941A4 (en) * 1999-06-21 2006-12-13 Murdoch Childrens Res Inst METHOD OF PROPHYLAXIS AND / OR TREATMENT OF CLINICAL DISORDERS
KR100681724B1 (ko) 1999-10-19 2007-02-28 머크 앤드 캄파니 인코포레이티드 티로신 키나제 억제제 및 이를 포함하는 약제학적 조성물
US7001735B2 (en) * 2000-03-01 2006-02-21 Albert Einstein College Of Medicine Of Yeshiva University Glucose transporter/sensor protein and uses thereof
DE60136277D1 (de) * 2000-07-19 2008-12-04 Takara Bio Inc Verfahren zum nachweis von krebs
CA2424689A1 (en) 2000-10-17 2002-04-25 Merck & Co., Inc. Orally active salts with tyrosine kinase activity
PA8535501A1 (es) 2001-01-05 2003-07-28 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina
US7071300B2 (en) * 2001-03-14 2006-07-04 Genentech, Inc. IGF antagonist peptides
CA2473039C (fr) 2002-01-18 2014-09-23 Pierre Fabre Medicament Nouveaux anticorps anti-igf-ir et leurs applications
FR2834991B1 (fr) 2002-01-18 2004-12-31 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
FR2834900B1 (fr) 2002-01-18 2005-07-01 Pf Medicament Nouvelles compositions a activite anti-igf-ir et anti-egfr et leurs applications
FR2834990A1 (fr) 2002-01-18 2003-07-25 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
US20050113577A1 (en) 2002-04-16 2005-05-26 Karki Shyam B. Solid forms of slats with tyrosine kinase activity
NZ536475A (en) * 2002-05-24 2008-06-30 Schering Corp Neutralizing human anti-igfr antibody
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
TW200401638A (en) 2002-06-20 2004-02-01 Bristol Myers Squibb Co Heterocyclic inhibitors of kinases
US6933386B2 (en) 2002-07-19 2005-08-23 Bristol Myers Squibb Company Process for preparing certain pyrrolotriazine compounds
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
WO2004013145A1 (en) 2002-08-02 2004-02-12 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
CA2514231A1 (en) 2003-02-13 2004-08-26 Pfizer Products Inc. Uses of anti-insulin-like growth factor i receptor antibodies
MXPA05009837A (es) 2003-03-14 2005-12-05 Pharmacia Corp Anticuerpos para el receptor del factor de crecimiento tipo insulina-i, para el tratamiento de canceres.
ES2383014T3 (es) 2003-04-02 2012-06-15 F. Hoffmann-La Roche Ag Anticuerpos contra el factor I de crecimiento similar a insulina y usos de los mismos
CA2524305C (en) 2003-05-01 2015-12-08 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
EP1631689A2 (en) * 2003-05-28 2006-03-08 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
ATE514783T1 (de) 2003-11-12 2011-07-15 Schering Corp Plasmidsystem zur expression mehrerer gene
PE20050928A1 (es) * 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
DE602005025685D1 (de) * 2004-12-03 2011-02-10 Schering Corp Biologische marker zur vorauswahl von patienten für die anti-igf1r-therapie
US20060233810A1 (en) * 2005-04-15 2006-10-19 Yaolin Wang Methods and compositions for treating or preventing cancer
AU2006259536A1 (en) * 2005-06-15 2006-12-28 Schering Corporation Anti-IGF1R antibody formulations
US20080112888A1 (en) † 2006-06-30 2008-05-15 Schering Corporation Igfbp2 biomarker
EP2145021A2 (en) * 2007-05-17 2010-01-20 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators

Similar Documents

Publication Publication Date Title
WO2008076278A4 (en) Methods of cancer treatment with igf1r inhibitors
JP2011519868A5 (enExample)
RU2010120674A (ru) Полностью человеческие анти-vegf-антитела и способы их применения
JP2011515478A5 (enExample)
JP2019503674A5 (enExample)
IL319363A (en) Cervalon ligands and bifunctional compounds containing them
JP2022549169A5 (enExample)
RU2018123481A (ru) Анти-lag3 антитела и антигенсвязывающие фрагменты
JP5816147B2 (ja) Ｉｇｆｂｐ２インヒビター
JP2016519091A5 (enExample)
MX2010012064A (es) Uso secuencial de agentes quimioterapeuticos citotoxicos para el tratamiento de cancer.
JP2017538673A5 (enExample)
RU2017145267A (ru) Модуляторы протеолиза на основе имидов и связанные с ними способы применения
CA2718918A1 (en) Methods for treating or preventing colorectal cancer
JP2013078341A (ja) 抗ｉｇｆ１ｒ療法に対する感受性のバイオマーカー
JP2014516964A5 (enExample)
JP2014516964A (ja) 治療用抗ｉｇｆ１ｒ合剤
US10512651B2 (en) Inhibition of MK2 in the treatment of cancer
US20240122906A1 (en) Methods of treating melanoma with ripretinib
US20160368980A1 (en) Inhibition of granulocyte colony stimulating factor in the treatment of cancer
JP2025509736A5 (enExample)
US20240209454A1 (en) Use of mutational signatures for multiple cancer types
US8470297B1 (en) FDG-pet evaluation of Ewing's sarcoma sensitivity
EP4626422A2 (en) Morphic forms of a mutant braf degrader and methods of manufacture thereof